Sentences with phrase «nilotinib for»
Moussa is an inventor on a Georgetown University patent application for use of nilotinib for the treatment of neurodegenerative disease.
https://gumc.georgetown.edu/
Moussa conducted the preclinical research that led to the discovery of nilotinib for the treatment of neuro - degenerative diseases, then partnered with Pagan for the clinical study.
Moussa and other Georgetown researchers are planning larger clinical trials with nilotinib for patients with Parkinson's and other similar diseases including Alzheimer's disease, likely to begin this year.
Also, Georgetown holds an issued US patent on related technology for the use of nilotinib for the treatment of certain neurodegenerative diseases and has other pending patent applications in US and foreign jurisdictions.
GUMC says its researchers are now planning larger clinical trials with nilotinib for patients with Parkinson's and other similar diseases including Alzheimer's disease, likely to begin in 2016.
Not exact matches
(Moussa is listed as an inventor on a patent application that Georgetown University filed related to nilotinib and the use of other tyrosine kinase inhibitors for the treatment of neurodegenerative diseases.)
In the proof of concept study, 12 patients received nilotinib, an FDA - approved drug for leukemia.
Druker said that Gleevec's long - term efficacy also offers a benchmark for comparative testing of two other similar kinase inhibitors, dasatinib and nilotinib, now underway.
In a significant, yet unusual judgment the Court of Justice of the European Union (CJEU) upheld the General Court's decision (T - 140 / 12; Teva Pharma v. EMA) that had affirmed the European Medicines Agency's (EMA) rejection of Teva's generic drug application for Glivec ® (active substance - imatinib), not due to the reference product's own orphan drug exclusivity but in view of orphan drug exclusivity of a similar medicinal product — Tasigna ® (active substance - nilotinib).
However, the General Court upheld the EMA's decision refusing Teva's generic application for imatinib in view of nilotinib's orphan drug exclusivity pertaining to CML.